A Combination of Muramylpeptides from Gram-Negative Bacteria Corrects Hematological and Immunological Disorders Induced by Cyclophosphamide
- Autores: Kiselevskii M.1, Anisimova N.1, Sitdikova S.1, Donenko F.1, Popilyuk S.2, L’vov V.3, Kalyuzhin O.4
-
Afiliações:
- Laboratory of Cellular Immunity, N. N. Blokhin National Medical Research Center, Ministry of Health of the Russian Federation
- CORUS Pharma Company, Resident of Biomedical Technologies Cluster, Skolkovo Foundation
- Laboratory No. 16 for Preparatory Biochemistry of Antigens, State Research Center Institute of Immunology, Federal Medial-Biological Agency
- Department of Clinical Immunology and Allergology, I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation
- Edição: Volume 167, Nº 3 (2019)
- Páginas: 371-374
- Seção: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/241704
- DOI: https://doi.org/10.1007/s10517-019-04529-6
- ID: 241704
Citar
Resumo
We have studied the effect of a combination of three natural muramylpeptides containing a meso-diaminopimelic acid residue (polyramyl) on the subpopulations of circulating T cells, spleen morphology, and leukocyte level in the blood of C57Bl/6 mice with cyclophosphamideinduced immunosuppression. Intraperitoneal injections of cyclophosphamide in a dose of 100 mg/kg on days 1, 3, 5, and 7 of the experiment reduced leukocyte count and the relative number of CD4+ T cells in the blood, and also depleted the cellular composition of splenic white pulp on day 10. Subcutaneous injections of polyramyl in a dose of 200 μg/mouse on days 8 and 9 practically completely restored blood leukocytes count and morphology of the splenic white pulp. Moreover, administration of polyramyl induced marked tendency to increase in the relative number of CD4+ T cells and CD4/CD8 ratio in mice with cyclophosphamideinduced immunosuppression.
Sobre autores
M. Kiselevskii
Laboratory of Cellular Immunity, N. N. Blokhin National Medical Research Center, Ministry of Health of the Russian Federation
Autor responsável pela correspondência
Email: kisele@inbox.ru
Rússia, Moscow
N. Anisimova
Laboratory of Cellular Immunity, N. N. Blokhin National Medical Research Center, Ministry of Health of the Russian Federation
Email: kisele@inbox.ru
Rússia, Moscow
S. Sitdikova
Laboratory of Cellular Immunity, N. N. Blokhin National Medical Research Center, Ministry of Health of the Russian Federation
Email: kisele@inbox.ru
Rússia, Moscow
F. Donenko
Laboratory of Cellular Immunity, N. N. Blokhin National Medical Research Center, Ministry of Health of the Russian Federation
Email: kisele@inbox.ru
Rússia, Moscow
S. Popilyuk
CORUS Pharma Company, Resident of Biomedical Technologies Cluster, Skolkovo Foundation
Email: kisele@inbox.ru
Rússia, Skolkovo, Moscow Region
V. L’vov
Laboratory No. 16 for Preparatory Biochemistry of Antigens, State Research Center Institute of Immunology, Federal Medial-Biological Agency
Email: kisele@inbox.ru
Rússia, Volokolamsk
O. Kalyuzhin
Department of Clinical Immunology and Allergology, I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation
Email: kisele@inbox.ru
Rússia, Moscow